Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab

Technology appraisal guidance
Reference number: TA357
Published: 07 October 2015
Last updated: 12 September 2017

History

Invitation to participate

Equality Impact Assessment (Guidance development) (PDF 155 KB)

Published:

02 November 2015

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final appraisal determination

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final appraisal determination information
Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final appraisal determination document (PDF 322 KB)

Published:

08 September 2015
Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: committee papers information
Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: committee papers (PDF 7.98 MB)

Published:

07 September 2015

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: scope consultation comments table

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: scope consultation comments table (PDF 208 KB)

Published:

26 February 2015

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final scope

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final scope (PDF 101 KB)

Published:

26 February 2015

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: equality impact assessment

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: equality impact assessment (PDF 121 KB)

Published:

26 February 2015

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final matrix

Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: final matrix (PDF 101 KB)

Published:

26 February 2015